Figures & data
![](/cms/asset/1cf0053d-77ca-45e8-9e8f-39b9f0535b02/tbbb_a_1553606_uf0001_oc.jpg)
Figure 1. FOXC2-AS1 and WISP1 mRNA expression were downregulated in mice with Dox-induced cardiotoxicity than in healthy mice.
Data here show the comparisons of FOXC2-AS1 (a) and WISP1 mRNA (b) expression between mice with Dox-induced cardiotoxicity and healthy mice.Notes:*, p < 0.05.
![Figure 1. FOXC2-AS1 and WISP1 mRNA expression were downregulated in mice with Dox-induced cardiotoxicity than in healthy mice.Data here show the comparisons of FOXC2-AS1 (a) and WISP1 mRNA (b) expression between mice with Dox-induced cardiotoxicity and healthy mice.Notes:*, p < 0.05.](/cms/asset/28b35f22-879d-421a-9513-d8556fd78a66/tbbb_a_1553606_f0001_oc.jpg)
Figure 2. FOXC2-AS1 and WISP1 mRNA expression were positively correlated in mice with Dox-induced cardiotoxicity but not in healthy mice.
Data here show the Pearson correlation coefficient analyses of the correlation between FOXC2-AS1 and WISP1 mRNA expression in mice with Dox-induced cardiotoxicity (a) and in healthy mice (b).
![Figure 2. FOXC2-AS1 and WISP1 mRNA expression were positively correlated in mice with Dox-induced cardiotoxicity but not in healthy mice.Data here show the Pearson correlation coefficient analyses of the correlation between FOXC2-AS1 and WISP1 mRNA expression in mice with Dox-induced cardiotoxicity (a) and in healthy mice (b).](/cms/asset/e8d1894a-eb2a-4953-a4d1-9224a26bcf4c/tbbb_a_1553606_f0002_b.gif)
Figure 3. FOXC2-AS1 overexpression increased viability of cardiomyocytes under Dox treatment.
Notes: *, p < 0.05.
![Figure 3. FOXC2-AS1 overexpression increased viability of cardiomyocytes under Dox treatment.Notes: *, p < 0.05.](/cms/asset/00f143c1-75e7-4fec-aa16-742d18210577/tbbb_a_1553606_f0003_oc.jpg)
Figure 4. FOXC2-AS1 overexpression is likely an upstream activator of WISP1 in cardiomyocytes.
Data here show the effects of FOXC2-AS1 overexpression on WISP1 protein expression (a) and the effects of WISP1 overexpression on FOXC2-AS1 expression under Dox treatment (10 ng/mL) (b), as well as the effects of FOXC2-AS1 overexpression on WISP1 protein expression with Dox treatment (c).Notes:*, p < 0.05.
![Figure 4. FOXC2-AS1 overexpression is likely an upstream activator of WISP1 in cardiomyocytes.Data here show the effects of FOXC2-AS1 overexpression on WISP1 protein expression (a) and the effects of WISP1 overexpression on FOXC2-AS1 expression under Dox treatment (10 ng/mL) (b), as well as the effects of FOXC2-AS1 overexpression on WISP1 protein expression with Dox treatment (c).Notes:*, p < 0.05.](/cms/asset/9b5dc16d-f5d7-484c-bd5b-c6be6bbb9e1c/tbbb_a_1553606_f0004_b.gif)